Metagenomi, Inc. (MGX)

7,00 0,00 (0,00%) Börsenschluss: 04:00PM EDT

Metagenomi, Inc.

5959 Horton Street
7th Floor
Emeryville, CA 94608
United States
510-871-4880
https://www.metagenomi.co

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 236

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Brian Charles Thomas Ph.D.	Co-Founder, CEO & Chairman of the Board	859,34k	N/A	1969
Dr. Jian Irish M.B.A., Ph.D.	President, COO & Director	729,82k	N/A	1964
Dr. Sarah B. Noonberg M.D., Ph.D.	Chief Medical Officer	591,49k	N/A	1968
Dr. Jak Knowles M.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Ms. Pamela M. Wapnick M.B.A.	Chief Financial Officer	N/A	N/A	1966
Dr. Luis G. Borges Ph.D.	Chief Scientific Officer	N/A	N/A	1962
Mr. Simon Harnest M.Sc.	Chief Investment Officer & Senior VP of Investor Relations	N/A	N/A	1987
Mr. Matthew L. Wein J.D.	Vice President of Corporate Legal, Compliance & Corporate Secretary	N/A	N/A	1971
Dr. Alan Brooks Ph.D.	Senior Vice President of Preclinical	N/A	N/A	1966
Dr. Christopher Brown	Head of Discovery	N/A	N/A	1989

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Corporate Governance

Metagenomi, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.